Merck & Co., Inc. Stock price

Equities

MRK

US58933Y1055

Pharmaceuticals

Delayed Nyse 04:02:44 2023-11-30 pm EST Intraday chart for Merck & Co., Inc. 5-day change 1st Jan Change
102.48 USD +1.33% +0.79% -7.63%
Sales 2023 * 59.92 B Sales 2024 * 63.03 B Capitalization 260 B
Net income 2023 * 630 M Net income 2024 * 18.75 B EV / Sales 2023 *
4,80x
Net Debt 2023 * 27.72 B Net Debt 2024 * 15.62 B EV / Sales 2024 *
4,37x
P/E ratio 2023 *
359x
P/E ratio 2024 *
13,5x
Employees 68,000
Yield 2023 *
2,88%
Yield 2024 *
3,16%
Free-Float 70.80%
More Fundamentals * Assessed data
Dynamic Chart
Merck Says FDA Grants Priority Review to Application for Keytruda Plus Padcev for Urothelial Cancer Treatment MT
FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer CI
Transcript : Merck & Co., Inc. Presents at The 6th Annual Evercore ISI HealthCONx Conference, Nov-30-2023 01:20 PM CI
Acclinate Collaborates with Merck to Increase Clinical Trial Diversity CI
Doubleverify Holdings Insider Sold Shares Worth $56,765,625, According to a Recent SEC Filing MT
Merck & Co., Inc. Announces Management Changes, Effective on December 4, 2023 CI
Merck Raises Quarterly Dividend to $0.77 Per Share; Payable Jan. 8 to Shareholders of Record on Dec. 15 MT
Merck Raises Quarterly Dividend 5.5% To 77 Cents DJ
Merck Declares Dividend for the First Quarter of 2024, Payable on January 8, 2024 CI
Merck: promising results for pneumococcal vaccine CF
Merck Says Phase 3 Trial of Pneumococcal Disease Vaccine Candidate V116 Showed 'Strong Evidence' of Immunogenicity MT
Merck Announces Results from STRIDE-3, a Phase 3 Trial Evaluating V116 CI
Hipgnosis Songs, founder Mercuriadis face legal claims RE
US Senate Health Committee Members Ask Johnson & Johnson, Merck, Bristol-Myers Squibb CEOs to Testify on Drug Pricing MT
Johnson & Johnson, Merck, Bristol Myers Squibb Invited to Testify to Senate Health Committee on Drug Prices MT
More news
1 day+1.33%
1 week+0.79%
1 month-0.21%
3 months-5.96%
6 months-7.18%
Current year-7.63%
More quotes
1 week
99.80
Extreme 99.8
102.69
1 month
99.80
Extreme 99.8
105.17
Current year
96.36
Extreme 96.36
119.65
1 year
96.36
Extreme 96.36
119.65
3 years
70.89
Extreme 70.89
119.65
5 years
65.25
Extreme 65.25
119.65
10 years
45.69
Extreme 45.69
119.65
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 2014
Director of Finance/CFO 54 1989
Chief Tech/Sci/R&D Officer 54 2020
Members of the board TitleAgeSince
Director/Board Member 63 2007
Director/Board Member 65 2015
Director/Board Member 69 2018
More insiders
Date Price Change Volume
23-11-30 102.48 +1.33% 29,299,666
23-11-29 101.13 +0.95% 10,286,779
23-11-28 100.18 -1.23% 8,738,483
23-11-27 101.43 -0.43% 7,356,536
23-11-24 101.87 +0.19% 3,167,952

Delayed Quote Nyse, November 30, 2023 at 04:02 pm EST

More quotes
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (18%); - sale of animal health products (9.4%); - other (2.9%). Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Calendar
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
30
Last Close Price
102.48USD
Average target price
123.61USD
Spread / Average Target
+20.62%
Consensus
1st Jan change Capi.
-7.63% 256 B $
+61.56% 532 B $
+48.29% 452 B $
-12.45% 366 B $
-11.89% 245 B $
-18.74% 217 B $
+1.83% 199 B $
-9.73% 197 B $
-40.53% 170 B $
+2.64% 143 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock Merck & Co., Inc. - Nyse
As early as today, start finding the best investment opportunities!
Optimize my profits
fermer